Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:collaboratesWith |
gptkb:Roche
|
| gptkbp:conditionStudied |
HER2-positive early breast cancer
|
| gptkbp:enrollment |
8381
|
| gptkbp:fullName |
Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation trial
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALTTO trial
|
| gptkbp:intervention |
gptkb:trastuzumab
gptkb:lapatinib lapatinib plus trastuzumab |
| gptkbp:location |
international
|
| gptkbp:number |
NCT00490139
|
| gptkbp:period |
Phase III
|
| gptkbp:principalInvestigator |
gptkb:Jose_Baselga
Martine Piccart |
| gptkbp:publicationYear |
2014
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:result |
disease-free survival
no significant improvement in disease-free survival with dual therapy compared to trastuzumab alone |
| gptkbp:sponsor |
gptkb:Breast_International_Group
GlaxoSmithKline |
| gptkbp:startYear |
2007
|
| gptkbp:bfsParent |
gptkb:Breast_International_Group
|
| gptkbp:bfsLayer |
5
|